Worldwide, it is estimated that there are nearly 2 billion women of reproductive age, and women comprise upwards of 70% of the total health care workforce \[[@CIT0001], [@CIT0002]\]. Pregnant women and women of reproductive potential are therefore at a high risk of contracting COVID-19. In a recent Centers for Disease Control and Prevention (CDC) report of 7162 patients with COVID-19 in the United States, as many as 2% of cases occurred in pregnant women \[[@CIT0003]\]. In prior work examining influenza, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS), pregnant women had increased morbidity and mortality when compared with nonpregnant women \[[@CIT0004]\]. Currently, there is insufficient evidence to determine whether the same is true for pregnant women with COVID-19. It is hypothesized that the natural physiologic state of immune tolerance associated with pregnancy may increase the risk of infection and severe complications \[[@CIT0007]\].

There is a need to identify safe and effective treatment options for pregnant persons with COVID-19, as there is for all populations, but there are multiple barriers preventing their inclusion in clinical trials. Due to safety concerns for the mother and the potential for teratogenicity, both pregnant and breastfeeding people are frequently excluded from clinical research studies, often in spite of established pharmacological safety data in pregnancy. However, drug metabolism (and therefore efficacy) in pregnancy differs from the general population, arguing for their inclusion in trials; optimal dosing requires special attention to physiologic changes (eg, increased glomerular filtration rate or decreased plasma albumin concentrations), which can alter pharmacokinetics and pharmacodynamics of drug concentrations. Fetal organogenesis also needs to be factored in when possible. Finally, as pregnancy is a state of immunologic change to accommodate the fetus, it is unclear how therapeutic immune-modulators used in COVID-19 (eg, tocilizumab and sarilumab) may impact maternal and fetal outcomes.

In this systematic review, we sought to highlight the heterogeneity of treatment and outcome data for pregnant persons with COVID-19 and summarize the literature related to COVID-19 in pregnancy. We provide an overview of the proportion of completed and actively recruiting interventional clinical trials permitting the inclusion of pregnant or breastfeeding individuals to underscore how frequently this population is ineligible for trial participation and to discuss the potential implications.

METHODS {#s1}
=======

Systematic Literature Review {#s2}
----------------------------

A systematic literature review was conducted to identify cases of COVID-19 in pregnancy that were reported as of June 29, 2020, following the PRISMA checklist. The first author searched PubMed/MEDLINE for all language publications and preprints using a combination of the following MeSH keywords: "pregnancy," "postpartum," "COVID-19," and "SARS-CoV-2." The first and third authors screened abstracts and reviewed the potential publications and references for relevance to identify any missing articles that were not identified using the above-listed keywords. Details as they pertained to presenting symptoms, any treatments received, and maternal, fetal/neonatal outcomes were recorded. Studies unrelated to cases of COVID-19 in pregnancy or the peripartum period were excluded.

Inclusion of Pregnant Women in COVID-19 Clinical Trials {#s3}
-------------------------------------------------------

A second search was conducted to identify COVID-19 clinical trials as of June 29, 2020, that reported pregnancy/breastfeeding as an exclusion criterion. ClinicalTrials.gov was searched for relevant studies, using the preprogrammed search terms "COVID-19," "SARS-CoV-2," "2019-nCoV," "2019 novel coronavirus," and "severe acute respiratory syndrome coronavirus 2." Inclusion and exclusion criteria were examined to determine whether pregnant and/or breastfeeding patients were excluded from the study. Studies listed as interventional clinical trials were then analyzed. Information related to the specific therapeutic intervention and the status of recruitment were summarized. Of the actively ongoing interventional clinical trials investigating the use of a drug (including dietary supplements and biologic agents) that did not report the exclusion of pregnant or breastfeeding women, the first author contacted study personnel for each of these studies by email to discern whether pregnant or breastfeeding women were eligible to be enrolled.

Patient Consent Statement {#s4}
-------------------------

Patient consent is not applicable, as this article is a systematic review.

RESULTS {#s5}
=======

Literature Review {#s6}
-----------------

In our systematic literature review, we identified 11 308 reported cases of COVID-19 in pregnancy and the postpartum period from a total of 52 case reports, 44 case series, 25 prospective/retrospective cohort studies, 3 governmental or national reports, and 2 case--control studies ([Table 1](#T1){ref-type="table"}, [Figure 1](#F1){ref-type="fig"}). Of those that reported estimated gestational age at the time of diagnosis (n = 2824), 77% (2184/2824) were in the third trimester of pregnancy (\>28 weeks), with the majority in the peripartum/postpartum period; 20% (574/2824) were in the second trimester, and 2% (66/2824) were in the first trimester.

###### 

Systematic Review of COVID-19 in Pregnancy and the Peripartum Period

  Total No. of Cases (n = 11 308)                   No. (%)
  ------------------------------------------------- -------------
  Estimated gestational age (n = 2824)^a^           
  1st trimester (1--12 wk)                          66 (2)
  2nd trimester (13--27 wk)                         574 (20)
  3rd trimester (\>28 wk)                           2184 (77)
  Symptoms (n = 11 308)                             
  Cough                                             2704 (24)
  Fever                                             2051 (18)
  Fatigue, malaise, myalgias                        1525 (13)
  Headache                                          1448 (13)
  Shortness of breath, dyspnea                      1391 (12)
  Other^b^                                          4120 (36)
  Asymptomatic                                      366 (3)
  Severity (as defined by authors; n = 1999)        
  Mild--moderate^c^                                 1583 (79)
  Severe/ICU                                        416 (21)
  Investigational treatment reported (n = 184)^d^   
  Hydroxychloroquine                                106 (58)
  Lopinavir/ritonavir                               39 (21)
  Remdesivir                                        13 (7)
  IL-1, IL-6 inhibitors                             13 (7)
  IVIG or gamma globulin                            9 (5)
  Convalescent plasma                               4 (2)
  Maternal outcomes (n = 10 597)                    
  Alive to delivery                                 10 437 (98)
  Died                                              33 (0.3)
  Still hospitalized                                127 (1.0)
  Pregnancy outcomes (n = 2297)                     
  Live births                                       1375 (60)
  In utero, pregnancy ongoing                       869 (38)
  Spontaneous miscarriage (\<20 wk)                 20 (0.9)
  Elective abortion                                 17 (0.7)
  Stillbirth (\>20 wk)                              14 (0.6)
  Ectopic pregnancy                                 2 (0.08)
  Gestational age at birth (n = 868)                
  Term                                              695 (80)
  Preterm (\<37 wk)                                 173 (20)
  Delivery type (n = 871)                           
  Vaginal delivery                                  259 (30)
  Cesarean section                                  612 (70)
  Neonatal outcomes (n = 1163)                      
  Alive                                             1155 (99)
  Neonatal death                                    8 (0.7)

Abbreviations: ICU, intensive care unit; IL, interleukin; IVIG, intravenous immunoglobulin.

^a^One large cohort study (n = 8207) did not have estimated gestational ages available.

^b^Other symptoms included diarrhea (n = 596), nausea/vomiting (n = 700), sore throat (n = 1005), loss of taste or smell (n = 803), and chills (n = 1016).

^c^Included asymptomatic cases.

^d^Treatment received at any time during pregnancy or postpartum after the time of COVID-19 diagnosis. Some women may have received multiple treatments.

![Search strategy of reported cases of COVID-19 in pregnancy in the literature.](ofaa350f0001){#F1}

The most common symptoms reported were cough (24%, 2704/11 308) and fever (18%, 2051/11 308), followed by fatigue, malaise, or myalgias (13%, 1525/11 308), headache (13%, 1448/11 308), and shortness of breath or dyspnea (12%, 1391/11 308); overall, \<5% were reported as entirely asymptomatic (366/11 308 or 3%). Not all studies reported maternal symptoms. The majority of these COVID-19 cases were mild to moderate in severity (79% \[1583/1999\]), with 21% (416/1999) being defined as severe or critical by the authors, requiring intensive care unit admission or intubation; 82% (9309/11308) did not comment on disease severity. Several women were reported to have developed disease or worsening of symptoms postpartum, though these instances and associated time intervals were not always reported; thus, no conclusions can be drawn related to the possibility of immune reconstitution given the heterogeneity of data. Overall, 98% of women (10 437/10 597) survived to delivery or hospital discharge. There were 33 maternal deaths, with 127 patients still hospitalized at the time of publication; 711 maternal outcomes were not reported.

The majority of cases did not report on pregnancy outcomes (80% \[9011/11 308\]), and 8% of pregnancies were ongoing at the time of publication (869/11 308). Among those that delivered and reported pregnancy outcomes, 96% (1375/1428) of women delivered a live birth (70% \[612/871\] via C-section). There were 20 spontaneous miscarriages, 17 elective abortions, 14 stillbirths, and 2 ectopic pregnancies. Overall 99% (1155/1163) of fetuses/neonates survived; there were 8 reported neonatal deaths. Neonatal testing for SARS-CoV-2 varied widely, making it challenging to draw any definitive conclusions about maternal fetal transmission. In many case series and case reports, SARS-CoV-2 was tested but not detected in amniotic fluid, breast milk, umbilical cord blood, placental tissue, or maternal vaginal secretions, nor was SARS-CoV-2 detected in neonatal serum, plasma, whole blood, feces, gastric secretions, or throat swabs. Overall, we only identified 41 neonates with possible SARS-CoV-2 infection based on positive polymerase chain reaction (PCR) or antibody tests performed on neonatal specimens (eg, nasopharyngeal/oropharyngeal swabs, blood, stool, and/or unspecified sites) ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}) \[[@CIT0008]\]. The following specimens were also found to be SARS-CoV-2 PCR or IgG/IgM positive: 9 placental specimens \[[@CIT0010], [@CIT0013], [@CIT0019], [@CIT0026]\], 3 umbilical cord blood \[[@CIT0018], [@CIT0019], [@CIT0027]\], 3 breast milk \[[@CIT0013], [@CIT0019], [@CIT0029]\], 3 maternal stool or rectal/anal swabs \[[@CIT0018], [@CIT0029]\], and 1 sample of maternal vaginal secretions \[[@CIT0013]\]. Several reports have discussed the placental pathology associated with maternal SARS-CoV-2 infection, but have not specifically assessed the placenta for the microbiologic presence of SARS-CoV-2 \[[@CIT0013], [@CIT0016], [@CIT0027], [@CIT0028], [@CIT0030]\].

Reports in the literature on treatment received by peripartum women with COVID-19 have varied greatly, or peripartum treatment was not reported. Overall, we found reports of 106 women who received hydroxychloroquine, 39 lopinavir/ritonavir, 13 remdesivir, 13 interleukin-1 (IL-1) or IL-6 inhibitors, and 9 intravenous immunoglobulin (IVIG) or gamma globulin either during pregnancy or during the postpartum period.

Inclusion of Pregnant Women in Ongoing Clinical Trials {#s7}
------------------------------------------------------

As of June 29, 2020, there were 2351 ongoing COVID-19-related clinical trials registered on ClinicalTrials.gov \[[@CIT0033]\]. Approximately 55% (1282/2351) were interventional clinical trials investigating the therapeutic use of a drug, device, procedure, screening/diagnostic tool, or behavioral intervention in reproductive-age adults (18--64 years); the remainder were observational studies or patient registries. Of the interventional studies, 65% (829/1282) specifically reported the exclusion of pregnant or breastfeeding women (76% \[715/942\] drug, dietary supplement, or biologic agent, 50% \[43/86\] device, 62% \[40/65\] procedure, 25% \[17/68\] screening/diagnostic tool, 12% \[14/121\] behavioral intervention). Of the chloroquine/hydroxychloroquine and lopinavir/ritonavir studies, at least 68% (75/109) and 80% (28/35), respectively, excluded pregnant or breastfeeding women despite widespread use in pregnancy for treatment of systemic lupus erythematosus and HIV \[[@CIT0034]\]. For convalescent plasma-related studies, at least 48% (44/91) reported the exclusion of pregnant or breastfeeding persons ([Supplementary Table 2](#sup2){ref-type="supplementary-material"}).

Of the 453 interventional studies registered on ClinicalTrials.gov that did not specifically mention the exclusion of pregnant or breastfeeding women, only 50% (227/453) were studies investigating the therapeutic use of a drug. Of these, 77 were not yet recruiting, 4 were withdrawn, and 1 was suspended---these studies were removed from further analyses. Of the remaining 145 trials, only 7% (10/145) reported specific inclusion of pregnant or breastfeeding patients. The remainder were contacted by email to verify whether pregnant and breastfeeding persons could be enrolled.

A further 38 studies whose investigators were contacted by email verified the inclusion of pregnant and breastfeeding patients; 18 were investigating use of convalescent plasma, 16 chloroquine/hydroxychloroquine, 10 various other drugs, 2 IL-6 inhibitors, and 2 remdesivir. The 2 remdesivir studies clarified that pregnant patients could be enrolled on a request for compassionate use basis only. One study assessing thromboprophylaxis clarified that only breastfeeding patients could be enrolled, and 1 hydroxychloroquine postexposure prophylaxis study reported inclusion of pregnant persons into the control arm only. Overall, 62 trials did not respond to email inquiries, 18 reported the exclusion of pregnant or breastfeeding women, 15 had no email address provided and could not be contacted, and 2 trials were either unsure or reported that they would discuss with an ethics committee ([Figure 2](#F2){ref-type="fig"}). A total of 48 completed or actively recruiting clinical trials reported the inclusion of pregnant or breastfeeding persons ([Table 2](#T2){ref-type="table"}).

![Search strategy of ongoing COVID-19-related clinical trials permitting the inclusion of pregnant or breastfeeding persons.](ofaa350f0002){#F2}

###### 

COVID-19-Related Clinical Trials Reporting Inclusion of Pregnant or Breastfeeding Women

  NCT Number                          Location                Study Name                                                                                                                                                                        Recruitment Number   Medication/Therapy Under Investigation
  ----------------------------------- ----------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- ---------------------------------------------
  Convalescent plasma                                                                                                                                                                                                                                                
  NCT04411602                         United States           Feasibility Study of Anti-SARS-CoV-2 Plasma Transfusions in COVID-19 Patients With SRD                                                                                            90                   
  NCT04342182                         Netherlands             Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study)                                                                                            426                  
  NCT04345523                         Spain                   Convalescent Plasma Therapy vs. SOC for the Treatment of COVID19 in Hospitalized Patients                                                                                         278                  
  NCT04347681                         Saudi Arabia            Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19                                                        40                   
  NCT04348656                         United States, Canada   CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)                                                                                          1200                 
  NCT04361253                         United States           Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy                                                                                                            220                  
  NCT04373460                         United States           Convalescent Plasma to Limit SARS-CoV-2 Associated Complications                                                                                                                  1344                 
  NCT04385199                         United States           Convalescent Plasma for Patients With COVID-19                                                                                                                                    30                   
  NCT04405310                         Mexico                  Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Double Blind 2 Center Trial                                                                                      80                   
  NCT04412486                         United States           COVID-19 Convalescent Plasma (CCP) Transfusion                                                                                                                                    100                  
  NCT04356482                         Mexico                  Convalescent Plasma for Ill Patients by COVID-19                                                                                                                                  90                   
  NCT04376034                         United States           Convalescent Plasma Collection and Treatment in Pediatrics and Adults                                                                                                             240                  
  NCT04388527                         United States           COVID-19 Convalescent Plasma for Mechanically Ventilated Population                                                                                                               50                   
  NCT04392232                         United States           A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection                                                                                             100                  
  NCT04397757                         United States           COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2                                                                       80                   
  NCT04421404                         United States           Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients                                                                    30                   
  NCT04364737                         United States           Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients                                                                                                      300                  
  NCT04381858                         Mexico                  Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia                                                                                                           500                  Convalescent plasma vs human immunoglobulin
  Hydroxychloroquine/chloroquine^a^                                                                                                                                                                                                                                  
  NCT04308668                         United States           Post-exposure Prophylaxis/Preemptive Therapy for SARS-Coronavirus-2                                                                                                               3000                 Hydroxychloroquine
  NCT04328467                         United States           Pre-exposure Prophylaxis for SARS-Coronavirus-2                                                                                                                                   3500                 Hydroxychloroquine
  NCT04323527                         Brazil                  Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2                                                                             440                  Chloroquine diphosphate
  NCT04328493                         Vietnam                 The Vietnam Chloroquine Treatment on COVID-19                                                                                                                                     250                  Chloroquine
  NCT04328961                         United States           Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)                                                                                                                   2000                 Hydroxychloroquine
  NCT04334148                         United States           Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine                                                                                                            15000                Hydroxychloroquine
  NCT04335552                         United States           Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection                                                               500                  Hydroxychloroquine, azithromycin
  NCT04350281                         Hong Kong               Double Therapy With IFN-beta 1b and Hydroxychloroquine                                                                                                                            80                   Hydroxychloroquine, IFN-beta 1b
  NCT04342169                         United States           University of Utah COVID-19 Hydroxychloroquine Trial                                                                                                                              400                  Hydroxychloroquine
  NCT04352933                         United Kingdom          PROLIFIC Chemoprophylaxis Trial (COVID-19)                                                                                                                                        1000                 Hydroxychloroquine
  NCT04354428                         United States           Treatment for COVID-19 in High-Risk Adult Outpatients                                                                                                                             630                  Hydroxychloroquine, azithromycin
  NCT04363450                         United States           Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)                                                                                                    1700                 Hydroxychloroquine
  NCT04364022                         Switzerland             Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland                                                               420                  Hydroxychloroquine, lopinavir/ritonavir
  NCT04435808                         United States           Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19                                                                                      350                  Hydroxychloroquine
  NCT04410562                         Spain                   Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy                                                          714                  Hydroxychloroquine
  Biologics                                                                                                                                                                                                                                                          
  NCT04327388                         Canada                  Sarilumab COVID-19                                                                                                                                                                300                  Sarilumab SAR153191
  NCT04317092                         Italy                   Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)                                                                                                                                    400                  Tocilizumab injection
  Antivirals                                                                                                                                                                                                                                                         
  NCT04292899^b^                      United States           Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19)                                            2400                 Remdesivir
  NCT04292730^b^                      United States           Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment   1600                 Remdesivir
  Other/multidrug combination                                                                                                                                                                                                                                        
  NCT02735707^c^                      Australia               Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia                                                                                     6800                 Various drug treatments
  NCT04381936                         United Kingdom          Randomised Evaluation of COVID-19 Therapy                                                                                                                                         12000                Various drug treatments
  NCT04342689                         United States           The Role of Resistant Starch in COVID-19 Infection                                                                                                                                1500                 Dietary supplement
  NCT04374461                         United States           A Study of N-acetylcysteine in Patients With COVID-19 Infection                                                                                                                   86                   N-acetylcysteine
  NCT04366960                         Italy                   Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients                                                                                    2712                 Enoxaparin
  NCT04367831                         United States           Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19                                                                       100                  Enoxaparin, heparin
  NCT0430824^d^                       United States           Covid-19 Associated Coagulopathy                                                                                                                                                  170                  Intermediate-dose thromboprophylaxis
  NCT04381962                         United Kingdom          A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2)                                          800                  Azithromycin
  NCT04319731                         United States           A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure                                                                                                  10                   Human amniotic fluid
  NCT04444271                         Pakistan                Mesenchymal Stem Cell Infusion for COVID-19 Infection                                                                                                                             20                   Mesenchymal stem cells

^a^One study (NCT04408456) reported that pregnant or breastfeeding persons would be included in the control arm only (not displayed here).

^b^Compassionate use basis only.

^c^Pregnant or breastfeeding women are excluded from particular study arms.

^d^Pregnancy is an exclusion criterion; breastfeeding is not.

DISCUSSION {#s8}
==========

Data regarding the clinical presentation, disease evolution, treatment, and outcomes for COVID-19 in pregnancy and lactation are scarce. Despite nearly 14 million cases of COVID-19 worldwide \[[@CIT0038]\], we identified only a few thousand reported cases of pregnant or breastfeeding persons with COVID-19. In general, published data mainly consist of case series and reports, and the information is heterogeneous, with outcome reporting subject to major bias and sometimes missing entirely. From the limited available literature, we found that when outcomes were reported, maternal and fetal/neonatal survival was overall excellent (98% and 99%) and that fetal/neonatal infection was rare but described.

We found that nearly two-thirds of completed or ongoing interventional COVID-19-related clinical trials have excluded pregnant or breastfeeding persons. This finding reaffirms prior reports \[[@CIT0039]\]. Despite available safety data in pregnancy for hydroxychloroquine and lopinavir/ritonavir, we were surprised to find that 68% and 80% of the respective clinical trials had excluded pregnant or breastfeeding persons. While some clinical trials may have had multiple study arms that might have prohibited the enrollment of this population due to known teratogenicity of other medications, many trials were singularly investigating hydroxychloroquine or lopinavir/ritonavir. Both the American College of Obstetrics and Gynecology and the American College of Rheumatology endorse the use of hydroxychloroquine in pregnancy for the treatment and management of systemic lupus erythematosus \[[@CIT0034], [@CIT0035]\] and lopinavir/ritonavir is one of the few drugs with an actual indication for pregnancy per the US Food and Drug Administration (FDA) \[[@CIT0040]\]. While recent evidence suggests that these drugs may not be effective in treating or preventing COVID-19 \[[@CIT0041]\], the large percentage of clinical trials that excluded pregnant persons should serve as a wake-up call to us all, including institutional review boards, regulatory authorities, and clinical trial investigators.

While we recognize that the inclusion of this population in clinical trials of investigational drugs is not without risk of harm to the fetus/neonate, the blanket exclusion of pregnant or breastfeeding persons from COVID-19 clinical trials has serious implications \[[@CIT0039]\]. Although we found that severe complications and death were rare (1%--2%), uncommon complications are important on a population level during a pandemic because of the sheer volume of cases (a 1% mortality rate still equates to 10 000 deaths if one were to examine 1 million cases). Furthermore, while published outcomes were reassuring, outcomes may be worse in developing countries with less access to critical care resources, making a safe and effective drug therapy all the more important.

Only when drugs are intended to be used in pregnancy does the FDA require pharmaceutical companies to demonstrate safety and efficacy in pregnancy \[[@CIT0045]\]. Between 1960 and 2013, only 1% of pharmacokinetic clinical trials were conducted with the inclusion of pregnant women \[[@CIT0046]\]. Through observation alone, it can take an average of 27 years to develop enough data to estimate the teratogenicity risk of a drug \[[@CIT0045]\], which is a prohibitively long timeline during a pandemic. Enrolling pregnant persons into clinical trials with their informed consent can help circumvent this delay. In our search, we came across 3 observational cohort studies specifically capturing information regarding the treatment of pregnant women (NCT04323839, NCT04319016, NCT04315870). While these studies will greatly increase our knowledge of the treatment and outcomes of this population, mores studies are needed, including examining the safety and efficacy of any potential vaccine.

To improve care for pregnant persons with COVID-19, pregnancy-specific adaptive clinical trials, similar to those for HIV \[[@CIT0047]\], should be considered. These can allow for pregnancy-specific expertise in the recruitment, consent, and assessment of pregnancy-related outcomes. Such studies could assess pharmacokinetics at varying stages in pregnancy to ensure dose optimization and can accommodate the rapid inclusion of promising new drugs that may emerge. These studies would complement ongoing clinical trials enrolling pregnant persons. A similar approach is currently underway for children (NCT04278404). For future and ongoing trials that include or enroll pregnant persons, there should be a mechanism in place to systematically capture longitudinal pregnancy outcomes. This may include consenting women for long-term follow-up should they become pregnant during the course of the trial. The availability of safety and efficacy data for investigational drugs for use in COVID-19 is paramount in order to properly counsel people who become pregnant during infection and/or following an unintentional exposure.

Our review of the literature was timely and is the first study (to our knowledge) to systematically examine and compile the available data related to treatment and outcomes of COVID-19 in pregnancy and related clinical trials. While we conducted a comprehensive search, our study has limitations. The major limitation relates to the data included in the published studies. There are several inherent biases (eg, recollection and publication bias) present in case series and observational studies. These may be especially prevalent in our review, given the extent of missing data and the lack of uniform reporting on important pregnancy and neonatal outcomes. Asymptomatic or mild cases of COVID-19 may have been underreported, and for cases that did not report outcomes, we cannot assume that none of these were without severe complications. Furthermore, not all studies reported detailed treatment information, and the majority of published cases described only the peripartum/postpartum period. Lastly, we only analyzed clinical trials reported on ClinicalTrials.gov and may have missed other important ongoing clinical trials registered elsewhere.

CONCLUSION {#s9}
==========

While we found reassuring maternal and fetal/neonatal outcomes with COVID-19, more rigorous, harmonized data collection and publication regarding all aspects of the disease, its treatment, and outcomes in pregnant and breastfeeding individuals are needed. Consideration should be given to establishing an international registry and pregnancy-specific adaptive clinical trials with coordinated data collection for important outcomes. We urge investigators and regulatory health agencies to work together to find a sound ethical approach to include this population of consenting adults in interventional trials. This will ensure that trial results are generalizable and that we have the necessary knowledge to guide safe, effective treatment in order to counsel the many pregnant and breastfeeding individuals who may go on to develop COVID-19 during this evolving pandemic.

Supplementary Data {#s10}
==================

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
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Click here for additional data file.
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Click here for additional data file.
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